Entering text into the input field will update the search result below

ALRN Aileron Therapeutics, Inc.
Stock Price & Overview

$2.42-0.05 (-2.02%)3:34 PM 12/04/23
NASDAQ | $USD | Post-Market: $2.30 -0.12 (-4.96%) 6:27 PM

Charts

FFO (FWD)
PE
Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Volume
Prev. Close

Quant Ranking

Ratings Summary

SA Analysts
Wall Street
Quant
Now3M ago6M ago
Valuation
-Rating: Not Covered
Growth
-Rating: Not Covered
Profitability
-Rating: Not Covered
Momentum
-Rating: Not Covered
Revisions
-Rating: Not Covered

See ALRN ratings with Premium.

People Also Follow

Company Profile

Aileron Therapeutics, Inc. logo
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
Employees
6
Founded
2001
Address
  • 285 Summer Street
  • Suite 101
  • Boston, MA, 02210
  • United States
Phone Number
617 995 0900
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.